Bortezomib-Cyclophosphamide-Dexamethasone (VCD) Vs Bortezomib-LenalidomideDexamethasone (VRD) in Newly Diagnosed Multiple Myeloma: A Matched Real-World Analysis from the Balkan Myeloma Study Group (BMSG)

Results

Title:	Bortezomib-Cyclophosphamide-Dexamethasone (VCD) Vs Bortezomib-LenalidomideDexamethasone (VRD) in Newly Diagnosed Multiple Myeloma: A Matched Real-World Analysis from the Balkan Myeloma Study Group (BMSG)
Authors :	Kastritis, Efstathios; ...; Bila, Jelena S. ; ...; Cvetković, Zorica P. ; Marković, Olivera B. ; ...; Sretenović, Aleksandra M.; ...; (broj koautora 20)
Issue Date:	2023
Publication:	Blood (65th Annual Meeting of the American Society of Hematology (ASH), San Diego, CA, DEC 09-12, 2023)
ISSN:	0006-4971 Blood Search Idenfier
Publisher:	[New York] : Elsevier
Type:	Conference Paper
Collation:	vol. 142 br. Suppl 1 str. 4734-4734
DOI:	10.1182/blood-2023-179416
WoS-ID:	001159740308223
URI:	https://enauka.gov.rs/handle/123456789/936682
Metadata source:	(Preuzeto iz Nasi u WoS)
M-category:	Mp. category will be shown later

Altmetric

Dimensions

Unpaywall

Google Scholar^TM